
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : iQ-007
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IQ-007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Resistant Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : iQ-007
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : iQ-007
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Keiretsu Mid-Atlantic
Deal Size : $0.6 million
Deal Type : Series A Financing
iQure Pharma Secures $600K in Early Closing to Research Neuropathic Pain Therapies
Details : The preclinical development of iQure's novel therapeutics iQ-007 and iQ-008. In addition, both compounds are supported by non-dilutive funding through the NIH epilepsy (ETSP) and NIH pain (PSPP) programs.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 31, 2022
Lead Product(s) : iQ-007
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Keiretsu Mid-Atlantic
Deal Size : $0.6 million
Deal Type : Series A Financing
